42.42 USD
↗ 1.55 (3.78%)PRE MARKET (AS OF 07:35 PM EDT)
Kodiak Sciences Inc Common Stock
KODNASDAQ • USD
Market: OPEN
Kodiak Sciences Inc Common Stock (KOD) is currently trading at $42.42. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jul 21, 2026.
Open?$41.24
High?$43.44
Low?$40.38
Prev. Close?$40.87
Volume?378.3K
Avg. Volume?800.7K
VWAP?$42.80
Rel. Volume?0.47x
Bid / Ask
Bid?$31.99 × 100
Ask?$51.30 × 100
Spread?$19.31
Midpoint?$41.64
Valuation & Ratios
Market Cap?2.7B
Shares Out?62.6M
Float?31.2M
Float %?49.9%
P/E Ratio?N/A
P/B Ratio?23.68
EPS?-$3.69
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Employees
124
Market Cap
2.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-04
Address
1250 PAGE MILL RD
PALO ALTO, CA 94304
Phone: 650-281-0850
PALO ALTO, CA 94304
Phone: 650-281-0850
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?10
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.23Distress
Confidence?55%Low
Short InterestSqueeze Risk
Short % of Float?34.05%Squeeze Risk
Short Interest?10.6M
Days to Cover?10.3
Free Float31.2M
Avg Daily Volume1.0M
Settlement Date2026-06-30
Financial Health
Current Ratio?3.54Strong
Quick Ratio?3.54Strong
Cash Ratio?3.42Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?23.68HIGH▾
Peers100
S&P3
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-11.4CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-205.8%WEAK▾
S&P3
ROA?-75.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-148118000
Enterprise Value?$2.5B
Fundamentals ratios updated end of day